Dr. Postow Discusses Side Effects with Combinations in Melanoma

Michael A. Postow, MD
Published: Monday, Mar 05, 2018



Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Side effects with combination therapies in melanoma remain a big issue, says Postow. The management of patients’ side effects while on therapy for melanoma is very important, whether it is with combination therapy or monotherapy.

One of the most powerful immunotherapy combinations, ipilimumab (Yervoy) plus nivolumab (Opdiv), does have many side effects despite its efficacy in treating melanoma. Postow says that they are currently trying to tweak that regimen to make it more tolerable for patients, while maintaining its efficacy.


Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Side effects with combination therapies in melanoma remain a big issue, says Postow. The management of patients’ side effects while on therapy for melanoma is very important, whether it is with combination therapy or monotherapy.

One of the most powerful immunotherapy combinations, ipilimumab (Yervoy) plus nivolumab (Opdiv), does have many side effects despite its efficacy in treating melanoma. Postow says that they are currently trying to tweak that regimen to make it more tolerable for patients, while maintaining its efficacy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x